about
Characterization of low molecular weight chemical fractions of dry bean (Phaseolus vulgaris) for bioactivity using Caenorhabditis elegans longevity and metabolite fingerprinting.Metabolomic profiling can predict which humans will develop liver dysfunction when deprived of dietary choline.Advances in NMR-based biofluid analysis and metabolite profilingCharacterization of in vitro metabolic profiles of cinitapride obtained with liver microsomes of humans and various mammal species using UHPLC and chemometric methods for data analysis.Metabolomic approach to evaluating adriamycin pharmacodynamics and resistance in breast cancer cells.Human urinary metabolomic profile of PPARalpha induced fatty acid beta-oxidation.Development of Metabolic Indicators of Burn Injury: Very Low Density Lipoprotein (VLDL) and Acetoacetate Are Highly Correlated to Severity of Burn Injury in Rats.Bioanalytical hydrophilic interaction chromatography: recent challenges, solutions and applications.Multivariate evaluation of pharmacological responses in early clinical trials - a study of rIL-21 in the treatment of patients with metastatic melanoma.Ca2+ effects on glucose transport and fatty acid oxidation in L6 skeletal muscle cell cultures.Discovery of common urinary biomarkers for hepatotoxicity induced by carbon tetrachloride, acetaminophen and methotrexate by mass spectrometry-based metabolomics.Serum metabolome analysis by 1H-NMR reveals differences between chronic lymphocytic leukaemia molecular subgroups.Genetic algorithms for simultaneous variable and sample selection in metabonomics.Meeting-in-the-middle using metabolic profiling - a strategy for the identification of intermediate biomarkers in cohort studies.The application of micro-coil NMR probe technology to metabolomics of urine and serum.
P2860
Q33908106-0D5CABFB-226B-4FD9-8F96-EF463D61FB7BQ34017163-63FFA1CE-EEA1-45B2-871E-A190DF25E5ADQ34109340-1FB99C0E-1E8B-49CF-8A52-8AE1AFAEB978Q34169406-12A60044-52DD-44C7-A271-B3C6727D12ACQ37161696-A0214004-BC67-4AE6-9CDD-931AE65BC9B4Q37383330-F9A69D70-0290-4897-BD42-036EF19A6C9FQ37512619-6AADEB2F-02C8-4152-BA08-878A35B1142EQ37810214-603F62FD-DDBB-49A7-99E8-821DDAAAF35EQ39871441-9B416F1C-AF91-4440-BAF4-B53CA02B840DQ41683287-0CE291B5-256C-4A04-9D8F-AA95B8E7E252Q42723225-AA5D096D-AAB4-40DC-905B-7D65DAC5ED33Q43187905-F9AD5ACE-43A1-4EE1-86E0-647C787FF4BEQ45190729-319A8FF5-DD44-4A9A-80C8-BAEEA4C493C4Q45335987-82D8C7EC-38B6-4C32-9777-B9A57FB0B267Q53435133-8CCB624B-25EF-4869-96F5-296468C90609
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on July 2007
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Application of metabonomics in drug development.
@en
Application of metabonomics in drug development.
@nl
type
label
Application of metabonomics in drug development.
@en
Application of metabonomics in drug development.
@nl
prefLabel
Application of metabonomics in drug development.
@en
Application of metabonomics in drug development.
@nl
P2860
P356
P1433
P1476
Application of metabonomics in drug development.
@en
P2093
Hector C Keun
Toby J Athersuch
P2860
P304
P356
10.2217/14622416.8.7.731
P577
2007-07-01T00:00:00Z